Enrolling by invitation
Not applicable
Effects of Different Exercises on Intrahepatic Lipid in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Condition(s) studied
Metabolic Dysfunction-Associated Steatotic Liver Disease
Investigational drug(s) / intervention(s)
Aerobic exerciseResistance exercisecombined exercise
Aerobic exercise: Intensity of exercise：Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR).
Time of aerobic exercise：from 30 to 45 minutes each day, five days a week.
Resistance exercise: The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 3 times a week.
Intensity of equipment trainings: 70% 1-RM. Exercise volume: 15-20 repetitions for a set, from 2 sets to 4 sets gradually.
Body weight trainings: 15-30 repetitions for a set, from 2 sets to 4 sets gradually.
combined exercise: Subjects conduct both aerobic and resistance trainings. Details of aerobic training session: Subjects conduct an aerobic exercise at 40-59% heart rate reserve(HRR) from 50-55 minutes each day, 3-4 days a week.
Details of resistance training session: The resistance exercise was consisted of equipment trainings and body weight trainings. Participants are required to exercise 2 times a week.
Study summary
This is a single-center, randomized, parallel controlled study to explore the effects of aerobic exercise, resistance exercise or aerobic combined resistance exercise on liver lipid in patients with MASLD, consisting of a 12-week core study followed by a 12-month extension phase.
Eligibility
Inclusion Criteria:
1. Metabolic dysfunction-associated steatotic liver disease pantients with high willingness and compliance;
2. Age: 18-45 years old;
3. BMI: 25-40kg/m2;
4. Liver MRI-PDFF \> 10%;
5. Weight change \<3% within 3 months before the intervention;
6. Being sedentary (≤60 minutes/week of moderate intensity exercise)
7. Without diabetes, or combined with type 2 diabetes (lifestyle control and glycated hemoglobin ≤7%).
Exclusion Criteria:
1. Patients with a history of excessive alcohol consumption: Excessive alcohol consumption was defined as an average daily consumption of more than 20g of ethanol in women and 30g in men.
2. Other types of chronic liver disease: such as viral hepatitis, cirrhosis, liver cancer, autoimmune liver disease, Wilson's disease, alpha-1 antitrypsin deficiency, hemochromatosis, drug-induced liver disease, etc.
3. Combined with other metabolic diseases: such as type 1 diabetes, hyperthyroidism, hypothyroidism, cushing syndrome, etc.
4. Patients with cardiovascular disease: such as uncontrolled hypertension, acute coronary syndrome, myocardial infarction, severe arrhythmia requiring medical therapy, etc.
5. Patients with cerebrovascular diseases: such as cerebral hemorrhage, ischemic stroke, etc.
6. Patients with the history of biliary obstruction, neuromuscular disease, skeletal deformity, severe osteoporosis, chronic kidney disease, and malignancy.
7. Patients used drugs which may have potential effects on MASLD within 1 year before randomization, including PPAR agonist, SGLT2 inhibitor, GLP1 receptor agonist, insulin, etc.
8. Patients with the history of bariatric surgery, major surgery within 8 weeks before randomization, etc,
9. Patients were enrolled in another clinical trial for the treatment of MASLD or weight loss within 1 year before randomization.
10. Pregnancy, lactation period, or women who plan to pregnant within 6 months before randomization.
11. Patients with mental healthy problems requiring medication.
12. Inability or unwillingness to undergo magnetic resonance imaging, including claustrophobia, implantable cardioverter defibrillators, and pacemakers.
13. Patients cannot complete 12-week exercise plan due to some reasons, such as frequent business trips.
14. After assessment, patients are not suitable or unable to participate in this clinical trial due to personal reasons.
Primary outcome measure(s)
- Changes of intrahepatic triglyceride contents — Baseline, 12 weeks
The changes of intrahepatic triglyceride contents were measured by MRI-PDFF.
Trial sites (2)
| Facility | City | Region | Status |
|---|
| Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School |
Nanjing |
Jiangsu |
|
| Department of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University Medical School |
Nanjing |
China |
|
More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China
Other trials for the same condition